PRRT2 and uveal melanoma: In preclinical studies, it has been shown to considerably reduce the viability of uveal melanoma cells harboring GNAQ/GNA11 mutations by inhibiting PKC isoforms, specifically through the PKC/NF-κB and PKC/ERK1/2 pathways [162,163].